JP2018505146A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505146A5
JP2018505146A5 JP2017533789A JP2017533789A JP2018505146A5 JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5 JP 2017533789 A JP2017533789 A JP 2017533789A JP 2017533789 A JP2017533789 A JP 2017533789A JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5
Authority
JP
Japan
Prior art keywords
amino
ethoxy
chem
acetyl
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533789A
Other languages
English (en)
Japanese (ja)
Other versions
JP6727210B2 (ja
JP2018505146A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/080969 external-priority patent/WO2016102562A1/en
Publication of JP2018505146A publication Critical patent/JP2018505146A/ja
Publication of JP2018505146A5 publication Critical patent/JP2018505146A5/ja
Application granted granted Critical
Publication of JP6727210B2 publication Critical patent/JP6727210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533789A 2014-12-23 2015-12-22 Fgf21誘導体及びその使用 Active JP6727210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
EP14199935.9 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505146A JP2018505146A (ja) 2018-02-22
JP2018505146A5 true JP2018505146A5 (enExample) 2018-11-29
JP6727210B2 JP6727210B2 (ja) 2020-07-22

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533789A Active JP6727210B2 (ja) 2014-12-23 2015-12-22 Fgf21誘導体及びその使用

Country Status (25)

Country Link
US (3) US9744213B2 (enExample)
EP (1) EP3236991B1 (enExample)
JP (1) JP6727210B2 (enExample)
KR (1) KR102427527B1 (enExample)
CN (1) CN107108709B (enExample)
AR (1) AR103246A1 (enExample)
AU (1) AU2015371056B2 (enExample)
CA (1) CA2972128A1 (enExample)
DK (1) DK3236991T3 (enExample)
ES (1) ES2742503T3 (enExample)
HK (1) HK1246156B (enExample)
HR (1) HRP20191292T1 (enExample)
HU (1) HUE044783T2 (enExample)
IL (1) IL252438B (enExample)
MX (1) MX377044B (enExample)
MY (1) MY181181A (enExample)
PL (1) PL3236991T3 (enExample)
PT (1) PT3236991T (enExample)
RS (1) RS59154B1 (enExample)
RU (1) RU2729011C2 (enExample)
SA (1) SA517381673B1 (enExample)
SI (1) SI3236991T1 (enExample)
TW (2) TWI681966B (enExample)
WO (1) WO2016102562A1 (enExample)
ZA (1) ZA201703768B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190117A1 (es) 2016-05-24 2019-01-16 Novo Nordisk As Compuestos de mic-1 y usos de estos
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
EP3678687B1 (en) * 2017-09-04 2022-08-17 89Bio Ltd. Mutant fgf-21 peptide conjugates and uses thereof
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
JP2024517327A (ja) 2021-05-11 2024-04-19 サイトカイ・ファーマ・アーペーエス インターロイキン-22の治療用誘導体
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS
AU2022341345A1 (en) * 2021-09-08 2024-03-28 Leto Laboratories Co., Ltd Fgf21 mutant protein and use thereof
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
PE20251082A1 (es) 2022-07-08 2025-04-10 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
AU2024241939A1 (en) 2023-03-30 2025-10-02 Novo Nordisk A/S Fusion compounds and uses thereof
AU2024272220A1 (en) * 2023-05-12 2025-10-16 Novo Nordisk A/S Long-acting growth hormone receptor antagonist and use thereof
AR133774A1 (es) 2023-09-11 2025-10-29 Novo Nordisk As Anticuerpos de dominio anti-il-6
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CA2549249A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合fgf−21化合物
US7576190B2 (en) 2004-05-13 2009-08-18 Eli Lilly And Company FGF-21 fusion proteins
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
ATE444307T1 (de) 2004-09-02 2009-10-15 Lilly Co Eli Muteine des fibroblasten-wachstumsfaktors 21
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子21の突然変異タンパク質
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2101822A2 (en) 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス,インコーポレイテッド 修飾fgf−21ポリペプチド
SI2068909T1 (sl) 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
EP2185178B1 (en) 2007-08-03 2017-08-23 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2358749B1 (en) * 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102361647B (zh) 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
US9655974B2 (en) * 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
EP2750695A2 (en) * 2011-08-31 2014-07-09 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
SG10202100667SA (en) * 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases

Similar Documents

Publication Publication Date Title
JP2018505146A5 (enExample)
RU2017125050A (ru) Производные fgf21 и их применения
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
JP2013533227A5 (enExample)
JP2012529463A5 (enExample)
JP2011526886A5 (enExample)
JP2016512425A5 (enExample)
JP2017528419A5 (enExample)
HRP20191614T1 (hr) Spojevi koji su suagonisti gip i glp-1
JP2017502024A5 (enExample)
RU2017101436A (ru) Mic-1 слитные белки и их применение
JP2012506402A5 (enExample)
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
JP2014224121A5 (enExample)
JP2016153410A5 (enExample)
JP2017081939A5 (enExample)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
NO20083793L (no) Antistoffer mot amyloid-beta peptid
JP2013518115A5 (enExample)
WO2012069836A3 (en) Biologically active complex and its preparation
WO2008138348A1 (en) Preparation of complexed lactalbumin
EP3963063A4 (en) COMPOSITIONS FOR THE TREATMENT OF PUMP DISEASE
JP2012115277A5 (enExample)